Beyond hazard ratios, investigators used restricted mean survival time (RMST) analysis to compare survival gains across trialed ICI combinations for mRCC.
The NDA is supported by data from a single-arm, multi-center, open-label, Phase II registration study in China that completed enrollment of 87 patients in March.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback